Metformin with jardiance
Pro Research Analysisby 
Searched over 200M research papers
Metformin with Jardiance: A Comprehensive Overview
Introduction to Metformin and Jardiance
Metformin and empagliflozin (marketed as Jardiance) are two prominent medications used in the management of type 2 diabetes. Metformin is a first-line treatment that helps to lower blood glucose levels by improving insulin sensitivity and reducing hepatic glucose production. Empagliflozin, on the other hand, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by preventing glucose reabsorption in the kidneys, leading to its excretion through urine1 3.
Combination Therapy: Metformin and Jardiance
Efficacy in Glycemic Control
Combining metformin with empagliflozin has been shown to significantly improve glycemic control in adults with type 2 diabetes. Clinical trials have demonstrated that this combination therapy not only lowers glycated hemoglobin (HbA1c) levels but also helps in reducing body weight and systolic blood pressure3. In a large phase III trial, empagliflozin as an add-on to metformin was found to be noninferior to glimepiride at 52 and 104 weeks and superior at 104 weeks in terms of HbA1c reduction3.
Safety and Tolerability
Empagliflozin, when used in combination with metformin, is generally well tolerated. Most adverse events reported in clinical trials were mild to moderate in intensity. Importantly, empagliflozin does not intrinsically increase the risk of hypoglycemia, although the risk is higher when combined with insulin or sulfonylureas3. This makes the combination a viable option for patients who need additional glycemic control without a significant risk of hypoglycemia.
Recommendations and Approvals
NICE Guidelines
The National Institute for Health and Care Excellence (NICE) has recommended empagliflozin as a treatment option for adults with type 2 diabetes, particularly when metformin, sulfonylurea, or pioglitazone are contraindicated or not tolerated2. This endorsement underscores the clinical utility of empagliflozin, either alone or in combination with metformin, in managing type 2 diabetes.
Pediatric Use
Empagliflozin, both as a standalone treatment (Jardiance) and in combination with metformin (Synjardy), has been approved for use in children aged 10 years and older1. This approval extends the benefits of this combination therapy to a younger population, providing an effective treatment option for pediatric patients with type 2 diabetes.
Conclusion
The combination of metformin and empagliflozin (Jardiance) offers a robust therapeutic option for managing type 2 diabetes. This combination not only enhances glycemic control but also contributes to weight loss and blood pressure reduction, with a favorable safety profile. The approval for pediatric use and recommendations by NICE further validate its efficacy and safety, making it a valuable addition to diabetes management protocols.
Sources and full results
Most relevant research papers on this topic
Empagliflozin (Jardiance) for type 2 diabetes in children.
Empagliflozin and metformin are now approved for use in children 10 years old with type 2 diabetes to improve glycemic control.
Three new treatments for diabetes recommended by NICE
NICE recommends canagliflozin, dapagliflozin, and empagliflozin as treatment options for adults with type 2 diabetes when metformin, sulfonylurea, or pioglitazone are contraindicated or not tolerated.
Rigorous JournalEmpagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Empagliflozin, a once-daily treatment for adult patients with type 2 diabetes, improves blood glucose control and reduces bodyweight and systolic blood pressure when combined with other antidiabetic drugs.
Literature ReviewWITHDRAWN: Metformin monotherapy for type 2 diabetes mellitus.
Metformin monotherapy effectively improves diabetes-related outcomes and reduces all-cause mortality in obese patients, but its effectiveness in overweight patients remains unclear.
Meta-Analysis
Very Rigorous Journal
Highly CitedMetformin as Anti-Aging Therapy: Is It for Everyone?
Metformin shows potential in retarding aging and reducing aging-related diseases, but its mechanisms and side effects need further study before it becomes a mainstay anti-aging therapy.
Literature ReviewHighly CitedQuantifying the Effect of Metformin Treatment and Dose on Glycemic Control
Metformin effectively lowers HbA1c levels in diabetic patients, and higher doses can potentially maximize glycemic control without increasing gastrointestinal effects.
Meta-AnalysisVery Rigorous JournalHighly CitedMetformin and Its Benefits for Various Diseases
Metformin offers benefits for various diseases and aging, with potential underlying mechanisms still unclear.
Highly CitedCardioprotection by Metformin: Beneficial Effects Beyond Glucose Reduction
Metformin has cardioprotective properties beyond glucose reduction, potentially improving heart health and reducing the risk of reinfarction and all-cause mortality in patients with coronary artery disease and congestive heart failure.
Meta-AnalysisVery Rigorous JournalMetformin: clinical use in type 2 diabetes
Metformin is a popular oral glucose-lowering medication for type 2 diabetes, with benefits including improved lipids, reduced cardiovascular events, and a lenient regulatory approach for patients with mild renal dysfunction.
Rigorous JournalHighly CitedMetformin ameliorates stress-induced depression-like behaviors via enhancing the expression of BDNF by activating AMPK/CREB-mediated histone acetylation.
Metformin can produce antidepressant effects by enhancing the expression of BDNF in stressed mice, through the activation of AMPK/CREB-mediated histone acetylation.
Rigorous JournalHighly Cited